Diabetic nephropathy is a progressive kidney disease caused by long-standing diabetes mellitus, characterized by glomerular hyperfiltration, thickening of the glomerular basement membrane, mesangial expansion, and nodular glomerulosclerosis (Kimmelstiel-Wilson lesions), ultimately leading to proteinuria and declining renal function.

Diabetic Nephropathy

Risk Factors

Understanding risk factors helps you identify who to screen more aggressively and what to modify.

Factor	Explanation
Genetic susceptibility	Strong familial clustering; first-degree relatives with DKD carry ↑ risk. Certain gene polymorphisms (e.g., ACE insertion/deletion polymorphism) influence susceptibility ^[3]
Race/Ethnicity	Blacks, Hispanics/Latinos at higher risk than Caucasians. Chinese populations have intermediate risk
Age	Older age → ↑ cumulative exposure to hyperglycaemia and haemodynamic stress
Duration of diabetes	The single strongest predictor — longer DM duration = more cumulative glomerular injury ^[1]^[3]

Factor	Mechanism
Poor glycaemic control (↑ HbA1c)	Sustained hyperglycaemia drives all the pathogenic mechanisms below (AGE formation, polyol pathway, PKC activation, etc.) ^[2]^[3]
Hypertension / Poor BP control	Transmits systemic pressure to glomerular capillaries → intraglomerular hypertension → mechanical stress on GBM → sclerosis ^[3]^[5]
Glomerular hyperfiltration (↑ GFR)	Seen early in DM course. Afferent arteriolar dilatation → ↑ intraglomerular pressure → glomerular hypertrophy → injury ^[3]
Obesity (↑ BMI)	Insulin resistance, adipokines, and haemodynamic factors worsen glomerular stress
Smoking	Endothelial dysfunction, ↑ oxidative stress, accelerates progression ^[2]^[3]
Hyperlipidaemia	Lipid deposition in mesangium (lipotoxicity), promotes inflammation

High Yield — Risk Factors for Diabetic Nephropathy

Risk factors: ↓GFR (i.e. glomerular hyperfiltration early, then declining GFR later), poor BP control, ↑HbA1c ^[4]. These are the "Big Three" modifiable risk factors and the basis of the management triad: glycaemic control + BP control + RAAS blockade.

Anatomy and Function: The Glomerular Filtration Barrier

To understand why diabetes damages the kidney, you need to understand the normal filtration barrier — because DN systematically destroys each of its layers.

Etiology (Focus on Hong Kong Context)

Diabetic nephropathy is the most common cause of CKD and ESRD in Hong Kong, reflecting the high and rising prevalence of T2DM in the territory.

Cause	Approximate %
Diabetic nephropathy	~35–51%
Glomerulonephritis (IgA nephropathy most common GN)	~25%
Hypertensive nephrosclerosis	~5%
Polycystic kidney disease	~5%
Unknown	~20%
Others (SLE, vasculitis, renovascular, congenital)	Remainder

^[4]^[5]

"Diabetic nephropathy is the most common cause of renal impairment → 51%" — this is the figure cited in the interactive tutorial ^[5]. Your job clinically is to identify the non-diabetic nephropathy cases among DM patients presenting with proteinuria.

Pathophysiology

This is the heart of understanding DKD. Diabetic nephropathy results from a complex interplay of metabolic, haemodynamic, and inflammatory pathways — not just one factor ^[1].

1. Metabolic Pathways of Injury

2. Haemodynamic Injury

Renal biopsy findings in diabetic nephropathy show a characteristic pattern ^[1]^[2]^[3]:

Feature	Description	Pathophysiological Basis
GBM thickening	Uniform thickening of the glomerular basement membrane	AGE cross-linking of collagen; ↑ ECM production by mesangial cells and podocytes
Mesangial expansion	Diffuse increase in mesangial matrix	↑ ECM deposition stimulated by TGF-β, AGEs, and hyperglycaemia
Nodular glomerulosclerosis (Kimmelstiel-Wilson nodules)	Mesangial cells develop nodular appearance due to repeated injury; PAS-positive acellular nodules	Progressive mesangial matrix accumulation becomes focal and nodular — pathognomonic of DKD
Arteriolar hyalinosis	Hyaline deposition in both afferent AND efferent arterioles	Insudation of plasma proteins through damaged endothelium; characteristic of DM (most other causes of hyalinosis only affect the afferent arteriole)
↑ Deposition of glycogenated product in matrix	Glycogen vacuoles (Armanni-Ebstein lesion) in tubular cells	Tubular reabsorption of excess filtered glucose
Arteriosclerosis + glomerulosclerosis	Combined vascular and glomerular damage	Both macro- and microvascular injury from DM

^[1]^[2]

Pathognomonic Finding

Kimmelstiel-Wilson nodules (nodular glomerulosclerosis) are pathognomonic of diabetic nephropathy, but they are only seen in ~25% of cases. Diffuse mesangial expansion is far more common and is a more sensitive (though less specific) finding. Both afferent and efferent arteriolar hyalinosis is highly characteristic of DM (other causes usually only affect the afferent arteriole).

The classic Mogensen staging (originally described for T1DM) remains a useful framework, though it is now understood that T2DM follows a broadly similar trajectory:

Stage	Time from DM Onset	Key Feature	GFR	Reversibility
1. Glomerular hyperfiltration	0–5 years	↑ GFR, enlarged kidneys	↑ (> 140 mL/min)	Reversible with glycaemic control
2. Silent (normoalbuminuria)	2–5 years	GBM thickening, mesangial expansion on biopsy; no clinical albuminuria	Normal or ↑	Structurally progressing but clinically silent
3. Incipient nephropathy (microalbuminuria)	5–15 years (T1DM); variable (T2DM)	Microalbuminuria: 30–300 mg/day (UACR 3–30 mg/mmol)	Normal or starting to ↓	Still potentially reversible with aggressive intervention
4. Overt nephropathy (macroalbuminuria)	10–20 years	Macroalbuminuria: > 300 mg/day (UACR > 30 mg/mmol); clinical nephrotic syndrome may develop	Declining (~10 mL/min/year without treatment)	Generally irreversible; aim is to slow progression
5. End-stage renal disease (ESRD)	15–30 years	Need for renal replacement therapy (RRT)	< 15 mL/min	Irreversible

^[2]^[4]

High Yield — Staging from Lecture Slides

Clinical features of diabetic nephropathy:

Glomerular hyperfiltration (0–5y): ↑ GFR
Microalbuminuria (5–10y): 30–300 mg/day albumin
Macroalbuminuria (10–15y): > 300 mg/day
Clinical nephrotic syndrome (diabetic glomerulosclerosis)
Progression to ESRD (15–30y) ^[4]

KDIGO Classification (Modern Staging for All CKD)

Current practice stages DKD using the KDIGO CKD classification combining eGFR (G1–G5) and albuminuria category (A1–A3), which provides a risk heatmap:

Category	Albuminuria (UACR)
A1 (normal/mildly increased)	< 3 mg/mmol (< 30 mg/g)
A2 (moderately increased, "microalbuminuria")	3–30 mg/mmol (30–300 mg/g)
A3 (severely increased, "macroalbuminuria")	> 30 mg/mmol (> 300 mg/g)

Stage	eGFR (mL/min/1.73m²)
G1	≥ 90
G2	60–89
G3a	45–59
G3b	30–44
G4	15–29
G5	< 15

CKD is defined as > 3 months of GFR < 60 mL/min/1.73m² OR ACR > 3 mg/mmol or other markers of kidney damage ^[7].

Clinical Features

Diabetic nephropathy is often asymptomatic in early stages — this is precisely why screening is critical. Symptoms generally appear only when disease is advanced.

Symptom	Stage	Pathophysiological Basis
Asymptomatic	Stages 1–3	Compensatory mechanisms maintain homeostasis; remaining nephrons hyperfiltrate
Peripheral oedema (ankle swelling progressing to generalised)	Stage 3–4	Proteinuria → hypoalbuminaemia → ↓ oncotic pressure → fluid shifts into interstitium (underfill theory). Additionally, primary tubular Na retention → volume expansion (overfill theory)
Periorbital oedema (morning)	Stage 4 (nephrotic)	In nephrotic syndrome, patients can lie flat (unlike heart failure) → fluid redistributes to dependent areas including periorbital tissues overnight → resolves during the day under gravity ^[6]
Frothy/foamy urine	Stage 3–4	Protein in urine acts like a surfactant → creates bubbles
Fatigue and malaise	Stage 4–5	Uraemia (accumulation of uraemic toxins); anaemia (↓ erythropoietin production by damaged kidneys)
Nausea, vomiting, poor appetite	Stage 5	Uraemic toxins directly irritate the GI tract and stimulate the chemoreceptor trigger zone
Nocturia	Stage 3–5	Loss of concentrating ability → obligatory water loss; also fluid redistribution from dependent oedema back to circulation when supine at night
Thirst	Stage 4–5	Metabolic acidosis → compensatory hyperventilation → dry mouth; also osmotic diuresis if glucose still elevated
Pruritus (itch)	Stage 4–5	Uraemic pruritus — multifactorial: retained uraemic toxins, secondary hyperparathyroidism (calcium-phosphate deposition in skin), altered opioid receptors ^[7]
Dyspnoea	Stage 5	Fluid overload (pulmonary oedema); metabolic acidosis (Kussmaul breathing); anaemia
Weight gain	Stage 3–5	Fluid retention

Sign	Stage	Pathophysiological Basis
Hypertension	Stage 2–5	RAAS activation (intrarenal and systemic); Na and water retention; endothelial dysfunction; ↑ sympathetic tone. Hypertension is both a cause and consequence of DKD — a vicious cycle ^[1]^[5]
Bilateral pitting oedema (lower limbs)	Stage 3–5	As above (proteinuria → hypoalbuminaemia → ↓ oncotic pressure; Na/water retention)
Periorbital oedema	Stage 4 (nephrotic)	Distinguishes renal from cardiac oedema — HF patients cannot lie flat (orthopnoea), so fluid cannot accumulate in the periorbital area; renal patients can lie flat → periorbital oedema present ^[6]
Pallor	Stage 3–5	Anaemia from ↓ EPO production; also dilutional anaemia from fluid overload
Café-au-lait skin	Advanced CKD	Retained urochromes deposited in the skin
Muehrcke's bands	Nephrotic stage	White bands on nails during transient hypoalbuminaemia (same mechanism as leukonychia/Terry's nails in CLD) ^[6]
Xanthelasma	Nephrotic stage	Hyperlipidaemia — hepatic lipogenesis ↑ as a non-specific reaction to ↓ oncotic pressure ^[6]
Fundoscopy: diabetic retinopathy	Concurrent	Diabetic nephropathy is almost always associated with other microvascular complications — always in T1DM, ~70% in T2DM ^[2]. Presence of diabetic retinopathy supports the diagnosis of DKD rather than a non-diabetic cause
Diminished peripheral pulses, bruits	Any stage	Macrovascular disease (atherosclerosis) common in DM; peripheral arterial disease, carotid and abdominal bruits ^[5]
Sensory neuropathy (glove-and-stocking)	Concurrent	Diabetic peripheral neuropathy — another microvascular complication; may coexist with foot ulcers, Charcot joints
Fluid overload signs (raised JVP, bibasal crepitations, sacral oedema)	Stage 4–5	Na/water retention exceeding compensatory mechanisms

Screening: UACR since diagnosis (T2DM) or 5 years after diagnosis (T1DM) ^[4].

Why the difference? T1DM has a clear onset (usually acute presentation), so you know when the hyperglycaemia clock started. T2DM is insidious — by the time of diagnosis, the patient may have had undiagnosed hyperglycaemia for years, so microvascular damage may already be present → screen immediately.

Parameter	Normal	Microalbuminuria (A2)	Macroalbuminuria (A3)
UACR	< 3 mg/mmol (< 30 mg/g)	3–30 mg/mmol (30–300 mg/g)	> 30 mg/mmol (> 300 mg/g)
24-hour urine albumin	< 30 mg/day	30–300 mg/day	> 300 mg/day

The gold standard is 24-hour urine protein quantification but this is cumbersome (patient has to collect all urine for 24 hours, may fake it by adding water) → now only used for research/studies ^[8].
UACR (urine albumin-to-creatinine ratio) is the preferred screening test, especially for DM and CKD patients. Done on the first morning void ^[8].
In QMH, uPCR (urine protein-to-creatinine ratio) is used instead of UACR — conversion formulae exist ^[8].

High Yield — Screening Protocol

Annual microvascular screen for all T2DM and T1DM ≥ 5 years from diagnosis (or ≥ 10 years old or at puberty). This involves: foot examination (including monofilament test), UACR, and dilated eye examination ^[2].

Your job is to find the non-diabetic nephropathy cases among DM patients with proteinuria ^[5]. Red flags include:

Red Flag	Why It Suggests Non-DKD
Haematuria (especially gross)	DKD produces a bland urinary sediment (no RBCs, no casts). Active sediment (RBC casts) suggests GN (e.g., IgA nephropathy, lupus nephritis)
Sudden/rapid decline in GFR	DKD is slowly progressive. Rapid GFR drop suggests AKI on CKD, RPGN, or drug-related injury
Short duration of diabetes (e.g., 2–3 years for T2DM)	Typically requires 15–20 years of hyperglycaemia for DKD to develop (though many T2DM patients are undiagnosed for years)
Absence of other microvascular complications (no diabetic retinopathy)	DKD almost never occurs in isolation. Absence of retinopathy in T1DM essentially rules out DKD
Systemic features (e.g., rash, arthralgia, haemoptysis)	Suggests systemic disease (SLE, vasculitis, Goodpasture syndrome)

^[5]

Exam Pearl

A common mistake is to assume that ALL proteinuria in a diabetic patient is from diabetic nephropathy. Remember to check for red flags. Renal biopsy may be indicated if red flags are present, to identify treatable non-diabetic causes (e.g., IgA nephropathy, membranous nephropathy).

Key Associations Worth Noting

Diabetic nephropathy rarely occurs in isolation — it is part of a systemic microvascular disease:

Complication	Prevalence with DKD	Connection
Diabetic retinopathy	>90% in T1DM with DKD; ~70% in T2DM	Same microvascular pathophysiology; retinopathy supports DKD diagnosis
Diabetic neuropathy	~70–90%	Peripheral neuropathy → foot ulcers → amputations (especially in the setting of PVD)
Macrovascular disease (IHD, CVD, PVD)	Very common	Shared risk factors (HTN, dyslipidaemia, endothelial dysfunction); IHD accounts for 70% of deaths in DM ^[2]

Approach to management depends on the stage of disease ^[1]:

Stage	Goal	Approach
Healthy DM patients → Prevention	Prevent nephropathy	Good glycaemic control
Incipient stage (microalbuminuria) → Still reversible	Reverse or halt progression	Good glycaemic control + treat other risk factors (BP, smoking) + pharmacological intervention: ACEI/ARB, SGLT2 inhibitors, GLP-1 receptor agonists
Overt complications → Macroalbuminuria, ↓ GFR	Retard progression	General measures (glycaemic control, risk factor management) + RAAS blockade + SGLT2i + consider finerenone

Key pharmacological agents ^[5]:

SGLT2i → massive reduction in risk of renal failure
ACEI/ARB → RAAS blockade very effective in preventing renal failure (but check renal artery stenosis status)
Non-steroidal mineralocorticoid receptor antagonist → finerenone
- Reduces kidney fibrosis
- More targeted molecular structure → hyperkalemia side effect much lower than conventional MRAs (spironolactone, eplerenone)
- Can combine with ACEI/ARB
GLP-1 receptor agonists → semaglutide (Ozempic)

High Yield Summary

Definition: Persistent albuminuria (UACR > 30 mg/g) or proteinuria (> 500 mg/day) in a DM patient without other renal disease.

Epidemiology: Leading cause of ESRD worldwide (~50%); in HK, accounts for ~35–51% of ESRD cases.

Risk Factors: Duration of DM, poor glycaemic control (↑HbA1c), hypertension, glomerular hyperfiltration, obesity, smoking, genetic susceptibility.

Pathophysiology (Two Arms):

Metabolic: AGEs, polyol pathway, PKC activation, hexosamine pathway, ROS (unifying mechanism) → ECM accumulation, GBM thickening, podocyte injury
Haemodynamic: Afferent arteriolar dilatation (↑SGLT2 → ↑Na reabsorption → ↓NaCl at macula densa → TGF reset) → intraglomerular hypertension → glomerular injury. RAAS activation constricts efferent arteriole → further ↑intraglomerular pressure.

Histology: GBM thickening, mesangial expansion, Kimmelstiel-Wilson nodules (pathognomonic), afferent + efferent arteriolar hyalinosis.

Stages: Hyperfiltration → Normoalbuminuria → Microalbuminuria (30–300 mg/day) → Macroalbuminuria (> 300 mg/day) → ESRD.

Clinical Features: Often asymptomatic early. Key features: proteinuria, nephrotic oedema, hypertension, renal failure. Almost always associated with other microvascular complications (retinopathy, neuropathy).

Red Flags for Non-DKD: Haematuria (especially active sediment), rapid GFR decline, short DM duration, absence of retinopathy, systemic features.

Screening: UACR — at diagnosis for T2DM; 5 years post-diagnosis for T1DM. Annual thereafter.

Key Drugs (preview): ACEI/ARB (RAAS blockade), SGLT2i (restore TGF, ↓intraglomerular pressure), finerenone (non-steroidal MRA, ↓fibrosis), GLP-1 RA. Glycaemic target HbA1c < 7–8%.

Active Recall - Diabetic Nephropathy (Definition, Epidemiology, Pathophysiology, Clinical Features)

Differential Diagnosis of Diabetic Nephropathy

The differential diagnosis must be approached in two layers:

Is the proteinuria/renal impairment actually from diabetic nephropathy, or from something else? (i.e., non-diabetic renal disease in a diabetic patient)
If not DKD, what else could cause proteinuria and/or declining GFR in this patient?

The mnemonic to remember the red flags for non-diabetic nephropathy (i.e., when to doubt the diagnosis of DKD) is "HARSH":

Letter	Red Flag	Why It Points Away from DKD
H	Haematuria (especially gross) or active urinary sediment (RBC casts, dysmorphic RBCs)	DKD produces a bland urinary sediment — no cells, no casts. Active sediment = glomerulonephritis ^[5]^[11]
A	Absence of other microvascular complications (especially no diabetic retinopathy)	DKD almost never occurs in isolation. In T1DM, absence of retinopathy essentially rules out DKD. In T2DM, ~70% with DKD have retinopathy ^[2]^[5]
R	Rapid decline in GFR	DKD is slowly progressive (~10 mL/min/year untreated). A rapid drop suggests AKI, RPGN, drug injury, or renal artery stenosis ^[5]^[11]
S	Short duration of DM (e.g., < 5 years for T1DM, 2–3 years for T2DM)	DKD typically requires 15–20 years of hyperglycaemia to develop in T2DM. However, many T2DM patients have been undiagnosed for years, so "short duration" must be interpreted with caution ^[5]^[11]
H	High suspicion features of systemic disease (rash, arthralgia, haemoptysis, weight loss)	Suggests SLE, vasculitis, Goodpasture syndrome, myeloma, or malignancy-associated nephropathy ^[11]^[14]

"Don't miss a RPGN. Don't forget the red flags that suggest the patient in front of you is NOT having diabetic nephropathy." ^[5]

Comprehensive Differential Diagnosis Table

The DDx is best organised by the primary clinical presentation pattern (nephrotic vs nephritic vs isolated renal impairment vs drug-related), because this is how you will encounter it at the bedside.

These are the diagnoses you must actively rule out. Diabetic nephropathy is classified as a secondary, non-proliferative glomerulopathy ^[12]^[13] — it presents with nephrotic-range proteinuria and a bland sediment. Other conditions in this category include:

Condition	Key Distinguishing Features	Why It Can Mimic DKD
Membranous nephropathy	Anti-PLA2R antibodies; subepithelial "spike and dome" deposits on biopsy; 2° causes: HBV/HCV, SLE, malignancy, drugs (captopril, gold, penicillamine)	Presents with nephrotic syndrome and bland sediment — identical to DKD clinically. MC cause of nephrotic syndrome in adults ^[14]. In HK, HBV is highly prevalent → HBV-related membranous nephropathy is a critical DDx
Focal segmental glomerulosclerosis (FSGS)	Steroid-resistant nephrotic syndrome; secondary causes include HIV, obesity, reflux nephropathy, drugs	Obesity-related FSGS is especially important in DM patients who are often obese. Can produce nephrotic-range proteinuria without haematuria
Minimal change disease (MCD)	MC cause of nephrotic syndrome in children; in adults, may be drug-induced (NSAID, COX-2 inhibitors) ^[9]; normal LM, podocyte effacement on EM	NSAID-induced MCD + acute tubulointerstitial nephritis (TIN) is a key DDx in a DM patient taking NSAIDs for pain who develops nephrotic syndrome + AKI ^[9]
Amyloidosis	Large kidneys (infiltrative); AL type (myeloma/plasma cell dyscrasia) or AA type (chronic inflammatory disease); Congo red staining; apple-green birefringence	Presents with nephrotic syndrome + renal impairment. Large kidneys on USS are a clue (DKD kidneys may also be large early, but most CKD kidneys are small) ^[7]
Light chain deposition disease / Cast nephropathy	Myeloma kidney; Lambda light chain restriction; tubular casts rimmed by macrophages; bone pain, anaemia, hypercalcaemia	"Atypical back pain → consider (1) multiple myeloma and (2) bony metastasis" ^[11]. In an elderly patient with AKI + proteinuria + anaemia, always think myeloma
Hypertensive nephrosclerosis	Long-standing HTN without DM, or HTN out of proportion to DM duration; bland sediment; small kidneys; arteriosclerosis on biopsy	Can co-exist with DKD. Difficult to distinguish clinically. Significant ↓GFR > 30% after starting ACEI/ARB should raise the possibility of renal artery stenosis and hypertensive nephrosclerosis ^[3]

DKD produces a bland sediment. If you find RBC casts, dysmorphic RBCs, or WBC casts, think of these:

Condition	Key Features	Relevance to DM Patient
IgA nephropathy	Most common primary GN worldwide and in HK; episodic gross haematuria with URTI; mesangial IgA deposits	Can co-exist with DKD in the same patient. Active sediment is the key distinguishing feature
Lupus nephritis	Young woman; ANA, anti-dsDNA positive; low C3/C4; multi-system disease (rash, arthralgia, serositis)	SLE → also think of potential distal RTA ^[5]. Lupus nephritis can range from Class I (minimal) to Class IV (diffuse proliferative — most severe)
RPGN / Crescentic GN	Rapid decline in GFR (days to weeks); requires urgent biopsy and treatment	Type I: anti-GBM (Goodpasture — linear IF); Type II: immune complex (granular IF); Type III: pauci-immune (ANCA-positive, negative IF). "Don't miss a RPGN" ^[5]
Post-streptococcal GN	Pharyngitis or skin infection 1–3 weeks prior; low C3; ASLO positive; "lumpy-bumpy" subendothelial deposits	Uncommon in the typical DKD age group but possible
Membranoproliferative GN (MPGN)	Low complement; HBV/HCV-related; "tram-tracking" of GBM	HBV/HCV highly prevalent in HK. Can cause nephrotic-nephritic overlap

Condition	Mechanism	How to Distinguish
Drug-induced AKI	NSAIDs: inhibit prostanoid production → impaired renal blood flow regulation; can also cause TIN and GN ^[11]. ACEI/ARB: efferent arteriolar dilatation → ↓ intraglomerular pressure → ↓ GFR (especially dangerous in bilateral renal artery stenosis) ^[11]. Contrast nephropathy: Cr ↑ ≥ 25% from baseline 48–72h after contrast	Temporal relationship to drug exposure. "Also enquire about the medications the patient took recently — consider drug-induced AKI" ^[11]. "Never prescribe ACEI and ARB together" ^[11]
Renal artery stenosis (RAS)	Atherosclerotic obstruction (common in DM patients who are vasculopaths); fibromuscular dysplasia (younger patients)	Renal bruit on P/E; severe refractory HTN; ↓GFR > 30% after starting ACEI/ARB; bland urinalysis ^[14]. Investigate with renal duplex ultrasound
Acute tubulointerstitial nephritis (TIN)	Drug allergy (antibiotics, NSAIDs, PPIs); infection; autoimmune	Sterile pyuria, WBC casts, eosinophilia (40% in NSAID-related TIN ^[9]); tubular dysfunction (hyperkalaemia, acidosis, polyuria)
Obstructive uropathy	Prostatic disease, stones, retroperitoneal fibrosis	USS showing hydronephrosis; post-renal cause. Common in elderly DM males with BPH
Cholesterol crystal embolisation	Post-vascular procedure in an atherosclerotic patient; livedo reticularis, blue toes, eosinophilia, low complement	DM patients are vasculopaths → at risk after angiography/vascular procedures

Diabetic nephropathy is classified under secondary non-proliferative (nephrotic) glomerulopathies ^[12]^[13]:

	Proliferative (Nephritic)	Non-Proliferative (Nephrotic)
Primary	IgA nephropathy, MPGN, Crescentic GN	MCD, FSGS, Membranous nephropathy
Secondary	Post-streptococcal GN, Lupus nephritis, HBV/HCV-related MPGN, Systemic vasculitis, Goodpasture syndrome	Diabetic nephropathy, Hypertensive nephrosclerosis, Amyloidosis, Light chain deposition disease, HIV-FSGS, Drug-induced, Reflux nephropathy

^[12]^[13]

This table is high yield. It tells you that:

If a DM patient has nephrotic features (heavy proteinuria, bland sediment, hypoalbuminaemia), DKD is likely but you must rule out membranous nephropathy, amyloidosis, FSGS.
If a DM patient has nephritic features (active sediment, haematuria, RBC casts), it is almost certainly NOT DKD — think IgA nephropathy, lupus nephritis, RPGN, MPGN.

USS Finding	Differential	Explanation
Small kidneys (< 10 cm)	CKD (any cause) — including late DKD	Chronic damage → nephron loss → fibrosis → shrinkage ^[7]
Normal-sized kidneys with ↑ creatinine	AKI (parenchymal, vascular, GN); early DKD	Damage too acute for kidneys to have shrunk yet. Requires biopsy ^[7]
Large kidneys	Early DKD (glomerular hypertrophy + hyperfiltration); Polycystic kidney disease; Amyloidosis (infiltrative); Obstruction (post-renal)	DKD kidneys may not be small even in ESRD (nephromegaly in early disease) ^[3]^[7]

Step	Action
1	Confirm DM diagnosis and duration
2	Screen for proteinuria (UACR) and assess GFR
3	Check urinary sediment — bland or active?
4	Look for other microvascular complications (retinopathy is key)
5	Review drug history for nephrotoxins
6	USS kidneys for size and obstruction
7	If red flags present → renal biopsy
8	If no red flags → clinical diagnosis of DKD, manage accordingly

High Yield Summary — DDx of Diabetic Nephropathy

When a DM patient presents with proteinuria and/or ↓GFR:

Most likely diagnosis: Diabetic nephropathy (~51% of renal impairment in DM).
Red flags for non-DKD (HARSH): Haematuria/active sediment, Absence of retinopathy, Rapid GFR decline, Short DM duration, High suspicion for systemic disease.
Key DDx with nephrotic features (bland sediment): Membranous nephropathy (especially HBV-related in HK), FSGS, amyloidosis, MCD (NSAID-induced), light chain deposition disease/myeloma.
Key DDx with nephritic features (active sediment): IgA nephropathy, lupus nephritis, RPGN, MPGN — these are almost certainly NOT DKD.
Non-glomerular DDx: Drug-induced AKI (NSAIDs, ACEI/ARB), renal artery stenosis, obstructive uropathy, TIN.
Renal biopsy is indicated only if atypical features are present.
DKD sits under secondary non-proliferative (nephrotic) glomerulopathies in the classification table.
Always check fundoscopy: presence of diabetic retinopathy strongly supports DKD; its absence is a major red flag.

Active Recall — Differential Diagnosis of Diabetic Nephropathy

References

^[2] Senior notes: Ryan Ho Endocrine.pdf (Section 4.1.4.2 Chronic Diabetic Complications, p.94–97) ^[3] Senior notes: Ryan Ho Urogenital.pdf (Section 3.4.6 Diabetic Nephropathy, p.84–85; Section 5.2.2, p.103) ^[5] Senior notes: Block A - Nephrology Interactive Tutorial.pdf (Case P2, p.4–5) ^[7] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (Kidney sizes on US, p.13) ^[9] Senior notes: Block A - Drugs and the Kidney.pdf (NSAID-induced nephrotic syndrome + AKI, p.14) ^[10] Lecture slides: GC_Interactive tutorial (Nephr case 2) student copy.pdf (Learning Objectives and Case History, p.1) ^[11] Senior notes: Block A – Nephrology Data Interpretation.pdf (DKD red flags p.4; DKD complicated by drug-induced TIN p.10–11) ^[12] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Classification of GN, p.995–997) ^[13] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (Classification of GN, p.402) ^[14] Senior notes: Maksim Medicine Notes.pdf (GN with nephrotic features, p.230–232; CKD aetiology, p.218) ^[15] Senior notes: Adrian Lui Pediatrics Notes.pdf (Classification of GN, p.313; Proteinuria approach, p.316; RPGN, p.326) ^[16] Senior notes: Ryan Ho Fundamentals.pdf (Isolated proteinuria, p.362)

Diagnostic Criteria, Diagnostic Algorithm, and Investigations for Diabetic Nephropathy

Diagnostic Criteria

Diabetic nephropathy is fundamentally a clinical diagnosis — you do not routinely biopsy every diabetic patient with proteinuria. The diagnosis is made when the clinical picture fits and there are no red flags suggesting an alternative renal disease. Understanding why it is a clinical diagnosis is important: DKD is so common (~51% of renal impairment in DM ^[5]) that performing a biopsy on every case would be impractical, costly, and expose patients to unnecessary risk. Biopsy is reserved for atypical presentations.

There is no single universal "diagnostic criteria set" for DKD in the way there is for, say, SLE or rheumatic fever. Instead, the diagnosis rests on a constellation of findings ^[1]^[3]^[13]:

Criterion	Detail
Established diagnosis of DM	T1DM or T2DM of sufficient duration (typically > 5 years for T1DM, variable for T2DM as onset is often unknown)
Persistent albuminuria	UACR ≥ 3 mg/mmol (≥ 30 mg/g) on at least 2 of 3 samples collected within 3–6 months (to exclude transient causes like fever, exercise, UTI)
Progressive decline in eGFR	Gradual, not sudden (rate ~10 mL/min/year without treatment in overt nephropathy)
Presence of other microvascular complications	Diabetic retinopathy is the strongest supportive feature — its presence strongly favours DKD. Always in T1DM, ~70% in T2DM ^[2]
Bland urinary sediment	No RBC and no casts — NOT acute glomerulonephritis ^[11]
Absence of features suggesting alternative renal disease	No haematuria, no systemic features, no rapid GFR decline, adequate DM duration

The older strict definition: persistent proteinuria > 500 mg/day in a 24-hour urine sample in a DM patient without other renal disease ^[3]^[13].

High Yield — GC Data Interpretation Diagnosis

From the Nephrology Data Interpretation case ^[11]:

Urine protein-to-creatinine ratio = 425 mg/mmol (normal < 15 mg/mmol)
24-hour urine protein = 5 g/day (nephrotic range ≥ 3.5 g/day, normal < 0.15 g/day)
Mid-stream urine = no RBC and no casts — NOT acute glomerulonephritis
Diagnosis = diabetic nephropathy

This is the exact diagnostic reasoning the in-house exam expects. Heavy proteinuria + bland sediment + DM of adequate duration + retinopathy = DKD. No biopsy needed.

Category	UACR	24h Urine Albumin	Clinical Significance
A1 (normal/mildly ↑)	< 3 mg/mmol (< 30 mg/g)	< 30 mg/day	Normal; no gross albuminuria — dipstick can only catch ≥ 200–300 mg/day ^[17]
A2 (moderately ↑ / "microalbuminuria")	3–30 mg/mmol (30–300 mg/g)	30–300 mg/day	Incipient DKD; still potentially reversible with aggressive intervention ^[4]
A3 (severely ↑ / "macroalbuminuria")	> 30 mg/mmol (> 300 mg/g)	> 300 mg/day	Overt DKD; generally irreversible; progresses to ESRD without treatment

"No gross albuminuria at the moment → dipstick can only catch 200 and above. So it is good that we caught it early, no overt diabetic nephropathy yet." ^[17] — This from the Endocrine Interactive Tutorial highlights why UACR is needed rather than relying on dipstick alone.

When a biopsy is performed, the RPS classification stages histological severity ^[13]:

Class	Histological Finding
Class I	Isolated GBM thickening (only seen on EM; LM appears normal)
Class II	Mild (IIa) or severe (IIb) mesangial expansion
Class III	≥ 1 Kimmelstiel-Wilson lesion (nodular glomerulosclerosis) with < 50% global glomerulosclerosis
Class IV	Advanced diabetic sclerosis with > 50% global glomerulosclerosis

The algorithm below integrates history, examination, urinalysis, blood tests, imaging, and the decision for biopsy. It reflects the approach taught in the GC Nephrology Interactive Tutorial ^[10] and Nephrology Data Interpretation ^[11].

Step-by-Step Explanation

Step 1 — Confirm and Quantify Albuminuria

UACR is the preferred screening test ^[8]^[4]. Done on the first morning void because overnight concentration makes it most sensitive.
Why not dipstick? Dipstick only detects albumin ≥ 200–300 mg/day ^[17] — it will miss microalbuminuria entirely. UACR catches disease at the A2 stage when it is still potentially reversible.
Gold standard is 24-hour urine protein quantification but it is cumbersome ^[8]. In QMH, uPCR is used instead of UACR — conversion formulae exist ^[8].
Must confirm on 2 of 3 samples over 3–6 months to exclude transient albuminuria (causes: fever, heavy exercise, UTI, heart failure, menstruation).

Step 2 — Assess Renal Function

Serum creatinine and eGFR (CKD-EPI equation preferred). Remember: when creatinine rises, GFR has already been reduced by at least 50% ^[5] — creatinine is an insensitive early marker.
Check electrolytes — K⁺ is particularly important (risk of hyperkalaemia from Type 4 RTA and from RAAS blockade).
HCO₃ — for metabolic acidosis (Type 4 RTA or uraemic acidosis).
Ca²⁺, PO₄²⁻ — for CKD-MBD if advanced disease.

Step 3 — Urinalysis: Characterise the Sediment

This is the single most important differentiating investigation.
Urine microscopy for RBCs, WBCs, and casts ^[18].
Heavy proteinuria + NO haematuria = non-proliferative glomerular disease (nephrotic pattern) / DM nephropathy / amyloidosis ^[19].
Proteinuria + haematuria + dysmorphic RBC + RBC casts = proliferative glomerular disease (nephritic pattern) ^[19] — this is NOT DKD.

Step 4 — Assess for Other Microvascular Complications

Dilated fundoscopy is essential. Presence of diabetic retinopathy strongly supports DKD; its absence is a major red flag ^[5].
Foot examination (monofilament test) for neuropathy.
Ask about autonomic symptoms (postural hypotension, gastroparesis, erectile dysfunction).

Step 5 — Renal Imaging

Ultrasound kidneys — non-invasive, assesses size, excludes obstruction and other structural lesions ^[13].
Normal kidney size = 10–12 cm, symmetrical.

Step 6 — Decision: Clinical Diagnosis vs Renal Biopsy

If no red flags → clinical diagnosis of DKD. No biopsy needed.
If red flags → renal biopsy indicated (see indications below).
Adults: immunological screen + renal biopsy, unless diagnosis is obvious (e.g., DM nephropathy, PLA2R+) ^[14].

Investigation Modalities: Detailed Breakdown

Investigation	What It Tells You	Key Findings in DKD	Interpretation Pearls
Urine dipstick	Rapid screening for proteinuria, haematuria, glucose, leukocytes, nitrites	Protein positive (2+ to 4+); RBC negative; glucose positive	Only detects albumin ≥ 300 mg/day (macroalbuminuria) — cannot detect microalbuminuria or Bence-Jones protein ^[14]
UACR (urine albumin-to-creatinine ratio)	Quantifies albuminuria; the preferred screening test for DKD	A2: 3–30 mg/mmol; A3: > 30 mg/mmol	First morning void is most accurate. Do on spot urine — no need for 24h collection ^[8]
uPCR (urine protein-to-creatinine ratio)	Quantifies total proteinuria	> 15 mg/mmol is abnormal; 425 mg/mmol in the Data Interpretation case ^[11]	Used in QMH instead of UACR ^[8]. Includes all proteins, not just albumin
24-hour urine protein	Gold standard for protein quantification	> 3.5 g/day = nephrotic range; > 0.5 g/day = overt DKD	Cumbersome; now only used for research ^[8]. Patient compliance is poor
Urine microscopy	Identifies cellular elements, casts, crystals	Bland sediment (no RBC, no RBC casts) in DKD	Active sediment (dysmorphic RBCs, RBC casts) → NOT DKD, think GN ^[11]^[19]. Oval fat bodies suggest nephrotic-range proteinuria
Urine culture (MSU)	Excludes UTI	Should be sterile in DKD	UTI can cause transient proteinuria — must exclude before diagnosing DKD

Exam Tip: Dipstick vs UACR

A common exam trap: the dipstick is negative for protein, so the student concludes "no nephropathy." But dipstick cannot detect microalbuminuria (< 300 mg/day). You need UACR to pick up early (A2) disease. Always order UACR in DM patients, regardless of dipstick result.

Investigation	What It Tells You	Key Findings in DKD	Why You Order It
Serum creatinine + eGFR	Renal function	↑ Cr, ↓ eGFR (progressive)	Stage the CKD (G1–G5). Remember: Cr is insensitive — GFR already ↓50% when Cr rises ^[5]
Serum urea	Renal function + hydration	↑ in CKD; urea:creatinine ratio > 100 suggests pre-renal ^[14]	Helps differentiate pre-renal from intrinsic cause if acute component
Serum albumin	Nephrotic status	< 30 g/L = hypoalbuminaemia (normal 34–54 g/L) ^[5]	Nephrotic syndrome if < 30 g/L with heavy proteinuria
Fasting glucose + HbA1c	Glycaemic control	HbA1c > 6.5% diagnostic of DM; higher values indicate poor control	HbA1c is for T2DM diagnosis — not for T1DM (medicolegal case) ^[17]. Guides glycaemic target (aim < 7–8%) ^[2]
Fasting lipid profile	CV risk; nephrotic features	↑ LDL, ↑ TG, ↓ HDL	Hyperlipidaemia is a feature of nephrotic syndrome AND a CV risk factor to manage ^[17]
Electrolytes: Na⁺, K⁺, HCO₃⁻	Metabolic complications	↑ K⁺ (Type 4 RTA, RAAS blockade); ↓ HCO₃⁻ (metabolic acidosis)	Type 4 RTA from JGA destruction. Check K⁺ before and after starting ACEI/ARB
Ca²⁺, PO₄²⁻, PTH, Vitamin D	CKD-MBD	↓ Ca, ↑ PO₄, ↑ PTH, ↓ active Vitamin D	Secondary hyperparathyroidism in advanced CKD
CBC	Anaemia, infection	Normocytic normochromic anaemia (↓ EPO in CKD)	Anaemia of CKD is an important complication to monitor ^[8]^[18]
Serum/urine protein electrophoresis	Myeloma, amyloidosis	Monoclonal band (M-spike) if myeloma	Rule out amyloidosis-related nephropathy ^[15]^[20] — especially in elderly with heavy proteinuria

These are not routine in typical DKD but are ordered when the diagnosis is in doubt to exclude non-diabetic renal diseases ^[6]^[14]:

Test	Target Condition
ANA, anti-dsDNA, C3/C4	Lupus nephritis
ANCA (c-ANCA, p-ANCA)	ANCA vasculitis / pauci-immune RPGN
Anti-GBM antibody	Goodpasture syndrome
Anti-PLA2R antibody	Primary membranous nephropathy
HBsAg, Anti-HCV, Anti-HIV	Secondary GN (membranous, MPGN, FSGS) — particularly important in HK given high HBV prevalence
ASLO titre	Post-streptococcal GN
Serum immunoglobulins, serum free light chains	Myeloma, amyloidosis, light chain deposition disease
Complement levels (C3, C4)	Low in lupus, MPGN, post-streptococcal GN, cryoglobulinaemia

High Yield — Nephrotic Syndrome Workup (from GC Lecture)

Evaluation for nephrotic syndrome ^[6]:

Full blood counts
Renal biochemistry
Urine protein quantification
Fasting glucose
Immune markers: Ig pattern, HBsAg, Anti-HCV, Anti-HIV, Anti-PLA2R
Tumour screening: CXR, stool OB, other relevant markers

This is the complete workup list from the GC lecture on glomerular diseases. In a DM patient where the diagnosis is obvious, you can abbreviate this. But if there are red flags, the full panel is needed.

Modality	Findings in DKD	Why You Order It
Ultrasound kidneys	Early DKD: normal or ↑ size (nephromegaly from hyperfiltration and hypertrophy). Late DKD: may be small (but DKD kidneys may not be small even in ESRD ^[3]). No hydronephrosis, no obstruction	Best, most non-invasive way to assess and visualise kidneys ^[7]. Assess size, exclude obstruction and other concomitant lesions ^[13]
Renal Doppler ultrasound	Renal artery stenosis (RAS)	Order if ↓GFR > 30% after starting ACEI/ARB — this suggests RAS ^[3]
CXR	Pulmonary oedema (fluid overload); cardiomegaly; rule out pulmonary TB (DM is a very common cause of TB reactivation ^[17])	Baseline and for assessing complications
ECG	LVH (from hypertension); ischaemic changes (macrovascular disease)	CV risk assessment — DM patients have a high burden of IHD

This is not optional — it is an essential diagnostic step.

Finding	Implication
Background diabetic retinopathy (dot/blot haemorrhages, microaneurysms, hard exudates)	Confirms microvascular disease → strongly supports DKD diagnosis ^[5]
Hypertensive retinopathy (silver wiring, AV nipping)	Confirms poorly controlled HTN → synergistic damage
Absence of any retinopathy	Major red flag — DKD almost never occurs without retinopathy in T1DM. In T2DM, absence should raise suspicion of alternative diagnosis ^[5]

Renal biopsy is only indicated if the diagnosis of diabetic nephropathy is uncertain ^[3]^[13]^[14].

Indications for biopsy in a DM patient with proteinuria/renal impairment ^[3]:

Indication	Reason
Haematuria or active urinary sediment	Suggests GN, not DKD
Absence of other microvascular complications (especially retinopathy)	DKD should not occur in isolation
Acute or too early onset of proteinuria (< 5y in T1DM)	Insufficient time for DKD to develop
Features of systemic disease (e.g., SLE, HBV/HCV, vasculitis)	Need to identify treatable cause
Significant ↓GFR > 30%, especially within 2–3 months of starting ACEI/ARB	Should raise the possibility of renal artery stenosis and hypertensive nephrosclerosis ^[3]
Rapidly progressive decline in GFR	RPGN — medical emergency

Histological findings on biopsy (if performed) ^[1]^[4]^[7]:

Technique	Typical DKD Finding
Light microscopy (LM)	Mesangial expansion, GBM thickening, Kimmelstiel-Wilson nodules (nodular glomerulosclerosis), arteriolar hyalinosis (both afferent AND efferent), arteriosclerosis
Immunofluorescence (IF)	Linear IgG along GBM (non-specific trapping); no immune complex deposition
Electron microscopy (EM)	GBM thickening (measurable), mesangial matrix expansion, podocyte foot process effacement
PAS stain	Highlights mesangial expansion and nodules

"Here we see a kidney with diabetic nephropathy, mesangial cell proliferation with classical Kimmelstiel-Wilson nodules" ^[7]

The table below shows how to interpret common investigation patterns:

Pattern	Urinalysis	eGFR	Albumin	USS	Most Likely Dx
Typical DKD	Protein 2-3+, RBC –, bland sediment	↓ progressively	↓ if nephrotic	Normal or large	Diabetic nephropathy
Non-diabetic GN in DM	Protein +, RBC +, dysmorphic RBCs, RBC casts	↓ variable	Variable	Variable	IgA nephropathy, Lupus nephritis, RPGN
Drug-induced AKI on CKD	May have WBC, eosinophils	Rapid ↑ Cr (e.g., 240 → 420)	Usually normal	Normal size	NSAID-induced TIN, ACEI/ARB toxicity
Myeloma kidney	Bence-Jones protein (dipstick-negative), tubular casts	↓	Variable	Normal or large	Light chain cast nephropathy
RAS	Bland	↓ > 30% after ACEI/ARB	Normal	Asymmetric kidneys, renal bruit	Renal artery stenosis

Population	When to Start	Test	Frequency
T2DM	At diagnosis	UACR	Annually
T1DM	5 years after diagnosis (or ≥ 10 years old or at puberty)	UACR	Annually
All DM	At diagnosis and annually	eGFR + UACR + dilated eye exam + foot examination	Annually

^[2]^[4]

Annual microvascular screen for all T2DM and T1DM ≥ 5y from dx or ≥ 10y or at puberty. Involves: foot examination (including monofilament test), UACR, and dilated eye exam. ^[2]

Case 2 from the GC Nephrology Interactive Tutorial ^[10]^[5]:

Presentation: 58-year-old man, DM for 11 years, HTN for 6 years, progressive ankle swelling.

Investigations ordered and their interpretation ^[11]:

Investigation	Result	Interpretation
Serum creatinine	210 μmol/L	↑ — renal impairment (normal 67–109)
Serum albumin	28 g/L	↓ — hypoalbuminaemia, nephrotic range (normal 34–54)
Urine multistix	Protein 3+, RBC negative	Heavy proteinuria with bland sediment → consistent with DKD
uPCR	425 mg/mmol	Markedly elevated (normal < 15)
24h urine protein	5 g/day	Nephrotic range (≥ 3.5 g/day)
MSU	No RBC, no casts	Confirms bland sediment — NOT GN
Fundoscopy	Background DR + hypertensive retinopathy	Microvascular complications present → supports DKD
BP	142/96 mmHg	Stage 2 hypertension → contributes to and results from DKD
Peripheral pulses	Diminished; carotid + abdominal bruits	Vasculopath → macrovascular DM complications

Diagnosis: Diabetic nephropathy ^[11]

No biopsy was needed because: long DM duration (11 years), nephrotic-range proteinuria with bland sediment, diabetic retinopathy present, no red flags.

High Yield Summary — Diagnostic Approach

Diabetic nephropathy is a clinical diagnosis made when ALL of the following are present:

Established DM of adequate duration
Persistent albuminuria (confirmed on ≥ 2 of 3 samples)
Bland urinary sediment (no RBC, no casts)
Other microvascular complications present (especially diabetic retinopathy)
No features of alternative renal disease

Key investigations:

UACR (screening and quantification — first morning void)
Serum creatinine + eGFR (staging)
Urine microscopy (bland vs active sediment — the key differentiator)
Dilated fundoscopy (presence/absence of retinopathy — the key clinical supportive evidence)
USS kidneys (size, exclude obstruction)
Renal biopsy — ONLY if atypical features (active sediment, no retinopathy, rapid GFR decline, short DM duration, systemic features, significant ↓GFR after ACEI/ARB)

Histology (when biopsy done):

GBM thickening, mesangial expansion, Kimmelstiel-Wilson nodules, afferent + efferent arteriolar hyalinosis
RPS Classification: Class I (GBM thickening) → Class IV (advanced sclerosis > 50% glomeruli)

Active Recall — Diagnostic Criteria, Algorithm, and Investigations for Diabetic Nephropathy

References

^[1] Lecture slides: Block A - Deterioration of eyesight in a diabetic patient_ diabetic complications.pdf (Diabetic Nephropathy section) ^[2] Senior notes: Ryan Ho Endocrine.pdf (Section 4.1.4.2 Chronic Diabetic Complications, p.94; Section B. Diabetic Nephropathy, p.97) ^[3] Senior notes: Ryan Ho Urogenital.pdf (Section 3.4.6 Diabetic Nephropathy, p.84–85; Section 5.2.2, p.103) ^[4] Senior notes: Maksim Medicine Notes.pdf (Diabetic nephropathy, p.89) ^[5] Senior notes: Block A - Nephrology Interactive Tutorial.pdf (Case P2, p.3–4) ^[6] Senior notes: Block A - Glomerular and Tubulo-interstitial Diseases and Acute Kidney Injury.pdf (Evaluation of nephrotic syndrome, p.22) ^[7] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (Kidney sizes, Biopsy, p.13, 16) ^[8] Senior notes: Block A - Introduction to Renal Investigations (RFT, urine tests and US kidneys).pdf (Urine tests, p.1, 4) ^[10] Lecture slides: GC_Interactive tutorial (Nephr case 2) student copy.pdf (Learning Objectives, Case History, p.1) ^[11] Senior notes: Block A – Nephrology Data Interpretation.pdf (DKD diagnosis, p.10; Drug-induced TIN, p.11; Diagnostic approach, p.1) ^[13] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (RPS Classification, p.1509; Case 2, p.1522–1524; Urinalysis interpretation, p.928–930) ^[14] Senior notes: Maksim Medicine Notes.pdf (Investigations, p.203–205; Nephrotic syndrome workup, p.230–232; AKI, p.214–216) ^[15] Senior notes: Adrian Lui Pediatrics Notes.pdf (Investigations table, p.314; Proteinuria approach, p.316) ^[17] Senior notes: Endocrine Interactive Tutorial.pdf (Lab interpretation, p.6–7) ^[18] Senior notes: Block A - Nephrotology Teaching Clinic RTD.pdf (Renal biopsy, p.3) ^[19] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Urinalysis interpretation, p.928–930) ^[20] Senior notes: Ryan Ho Urogenital.pdf (Commonly utilised investigations table, p.55)

Management of Diabetic Nephropathy

Detailed Management by Pillar

These are the non-negotiable foundations that apply to every patient, at every stage.

Intervention	Detail	Mechanism / Rationale
Smoking cessation	Absolute	Smoking causes endothelial dysfunction, ↑ oxidative stress, accelerates atherosclerosis and glomerulosclerosis
Weight reduction	Target BMI < 25 (or at least 5–10% weight loss if obese)	↓ Insulin resistance, ↓ intraglomerular pressure, ↓ adipokine-mediated inflammation
Exercise	≥ 150 min/week moderate-intensity aerobic activity	↑ Insulin sensitivity, ↓ BP, improves lipid profile
Dietary sodium restriction	Low salt (Na⁺) diet — restrict to ~2 g/day Na (~5 g NaCl) ^[13]	↓ Extracellular fluid volume → ↓ BP; potentiates the effect of RAAS blockade (ACEI/ARB are less effective in high-salt states because salt loading stimulates aldosterone escape)
Dietary protein restriction	Protein restriction of 0.6–0.8 g/kg/day ^[13]	↓ Glomerular hyperfiltration (high-protein diet causes afferent arteriolar dilatation via amino acid-induced ↑ GFR); ↓ urea generation; slows rate of GFR decline

Protein Restriction — A Nuance

Protein restriction of 0.6–0.8 g/kg/day is recommended to stabilise or slow the rate of decline of renal function ^[13]. However, in active nephrotic syndrome, protein restriction is NOT recommended because heavy urinary protein loss means the patient is already protein-depleted — they should have normal protein intake as ↑ albumin excretion is associated with poorer outcomes ^[20]^[21].

Parameter	Target	Rationale
HbA1c	< 7% in general ^[13]; < 7–8% in those with CKD/comorbidities ^[2]	Reduces incidence of progression from incipient nephropathy to overt nephropathy ^[13]. Too aggressive (< 6.5%) → ↑ risk of hypoglycaemia, especially in CKD where drug clearance is reduced
Less stringent targets	HbA1c < 8%	Multiple comorbidities, short life expectancy, high risk of hypoglycaemia (extremes of age) → requires individualisation ^[22]

Choice of anti-diabetic agents in CKD:

This is a high-yield topic because drug dosing changes as GFR declines. Several agents are contraindicated or need adjustment in renal impairment.

Drug Class	Drug	Renal Considerations	Mechanism of Action
Biguanide	Metformin	Contraindicated when eGFR < 30 (risk of lactic acidosis due to impaired renal clearance). Stop at ESRD ^[4]. Dose reduction at eGFR 30–45	↓ Hepatic gluconeogenesis, ↑ insulin sensitivity. The "met-" in metformin = methyl group on the biguanide backbone
SGLT2 inhibitor	Empagliflozin, dapagliflozin, canagliflozin	Renoprotective effect persists even at low GFR. Current guidelines: can initiate down to eGFR ≥ 20 mL/min (2024 KDIGO). Stop at ESRD/dialysis (no functioning nephrons → no site of action) ^[4]^[5]	Blocks sodium-glucose co-transporter 2 in proximal tubule → glucosuria + natriuresis → restores TGF → ↓ intraglomerular pressure
GLP-1 receptor agonist	Semaglutide (Ozempic), liraglutide, dulaglutide	No dose adjustment needed for renal impairment (not renally cleared). Safe in CKD	Incretin mimetic → ↑ glucose-dependent insulin secretion, ↓ glucagon, slows gastric emptying, promotes satiety/weight loss. Also has direct anti-inflammatory + anti-fibrotic renal effects
DPP-4 inhibitor	Linagliptin (Tradjenta)	Most convenient in renal impairment — hepatobiliary elimination, no need to change dose according to renal function ^[9]. Other DPP-4i (sitagliptin, saxagliptin) need dose reduction	Inhibits dipeptidyl peptidase-4 → prevents degradation of endogenous GLP-1 and GIP → ↑ insulin, ↓ glucagon
Sulphonylurea	Glipizide preferred in CKD; gliclazide acceptable	Avoid glibenclamide (long-acting active metabolite → ↑ hypoglycaemia risk in CKD). Gliclazide is hepatically metabolised — safer	Directly stimulates β-cell insulin secretion via SUR1 receptor
Insulin	All types	Safe at all stages of CKD. But insulin clearance is reduced in CKD → dose often needs to be ↓ to avoid hypoglycaemia	Exogenous insulin replacement
TZD	Pioglitazone	Use with caution — fluid retention (worsens oedema). Pioglitazone and saxagliptin → both shown to have increased risk of heart failure ^[1]	PPARγ agonist → ↑ insulin sensitivity

ESRD Drug Rule

At ESRD: stop metformin and SGLT2i. Use drugs that are not renally metabolised: glipizide, linagliptin, insulin ^[4].

Parameter	Target	Evidence
BP target	< 130/80 mmHg (T2DM) or < 120/75 mmHg (T1DM) ^[13]	Decreases systemic BP and hence intraglomerular pressure ^[13]. Reduces both CV events and rate of albuminuria progression
Number of agents	Majority of patients with DKD require ≥ 2 anti-hypertensive agents ^[13]	Single-agent therapy is rarely sufficient due to the multifactorial nature of hypertension in DM (volume overload + RAAS activation + endothelial dysfunction + sympathetic overactivity)

Drug of choice:

ACEI or ARB is the preferred first-line antihypertensive in DKD — they provide BOTH anti-hypertensive and renal protective effects ^[5]^[13]^[21].

This is the single most important pharmacological intervention in DKD (along with SGLT2i).

Feature	Detail
Indication	All patients with DKD — even if BP is normal ^[4]. In ALL glomerulonephropathy ^[20]^[21]
Mechanism	ARBs reduce intraglomerular pressure by blocking angiotensin II-induced efferent arteriolar constriction → ↓ glomerular capillary pressure → ↓ proteinuria. Also reduce proximal tubular angiotensinogen production and collecting duct renin, and protect glomerular endothelium and podocyte ^[17]
Goal	↓ Urinary albumin loss and rate of progression to ESRD. Keep proteinuria < 1 g/day or uPCR < 0.5–1 g/g ^[20]^[21]
Monitoring	Check serum K⁺ and creatinine 1–2 weeks after starting or dose titration. A rise in creatinine of up to 25–30% is acceptable (reflects ↓ intraglomerular pressure). If ↓GFR > 30% → suspect renal artery stenosis ^[3]^[11]

Contraindications and Cautions:

Contraindication	Reason
Bilateral renal artery stenosis	Both kidneys depend on angiotensin II-mediated efferent arteriolar constriction to maintain GFR. Blocking this → precipitous GFR decline → AKI ^[11]
Severe hyperkalaemia (K⁺ > 5.5 mmol/L)	ACEI/ARB ↓ aldosterone → ↓ K⁺ excretion → further ↑ K⁺. DKD patients already prone to hyperkalaemia (Type 4 RTA) ^[5]^[13]
Pregnancy	Teratogenic (renal agenesis, oligohydramnios)
Never prescribe ACEI and ARB together	Dual RAAS blockade → ↑ hyperkalaemia, ↑ AKI, no additional CV benefit (ONTARGET trial) ^[11]

Exam Pearl: ACEI/ARB Safety Check

"Never prescribe ACEI and ARB together" ^[11]. "ACEI and ARB are contraindicated in patients with bilateral renal artery stenosis" ^[11]. "Cautious in inducing hyperkalaemia in patients with established CKD" ^[13]. These are direct exam-tested facts from the GC Data Interpretation lecture.

Feature	Detail
Drugs	Empagliflozin, dapagliflozin, canagliflozin
Name breakdown	"SGLT2" = Sodium-Glucose Linked Transporter 2; "-gliflozin" suffix = SGLT2 inhibitor
Renal mechanism	Blocks Na⁺/glucose co-transport in proximal tubule → ↑ NaCl delivery to macula densa → restores tubuloglomerular feedback → afferent arteriolar constriction → ↓ intraglomerular pressure → ↓ hyperfiltration → ↓ albuminuria
Additional benefits	Natriuresis → ↓ BP; ↓ weight (glucosuria = calorie loss); ↓ uric acid; anti-inflammatory and anti-fibrotic effects; cardiorenal benefits independent of glucose lowering
Landmark trials	EMPA-REG OUTCOME, CREDENCE, DAPA-CKD, EMPA-KIDNEY
When to start	Current KDIGO 2024: can initiate at eGFR ≥ 20 mL/min. Continue until dialysis or transplant
When to stop	ESRD on dialysis (no functioning nephrons = no site of action) ^[4]
Side effects	Genital mycotic infections (glucosuria creates a sugar-rich environment → fungal overgrowth), euglycaemic DKA (rare but important — ↓ insulin, ↑ ketogenesis), volume depletion, UTI

"SGLT2i → massive reduction in risk of renal failure" ^[5]

This is a newer addition to the DKD management armamentarium, emphasised heavily in the Interactive Tutorial ^[5].

Feature	Detail
Drug	Finerenone
Name breakdown	"Fine-" is brand specific; "-renone" = MRA class. "Non-steroidal" distinguishes it from spironolactone and eplerenone, which are steroidal MRAs
Mechanism	Blocks mineralocorticoid receptor (MR) → reduces kidney fibrosis (MR activation in the kidney drives TGF-β, ECM deposition, and inflammatory cell recruitment). Also ↓ cardiac fibrosis
Key advantages over spironolactone/eplerenone ^[5]	Molecular structure permits finerenone to be much more targeted → hyperkalaemia side effect much lower than conventional MRAs. Can be combined with ACEI/ARB (since ACEI/ARB already increase hyperkalaemia risk, using a lower-risk MRA is crucial)
Evidence	FIDELIO-DKD, FIGARO-DKD trials → ↓ composite kidney outcome, ↓ CV events in DKD
Indications	DKD with persistent albuminuria despite maximised ACEI/ARB + SGLT2i
Contraindications	Severe hyperkalaemia (K⁺ > 5.0 before starting); adrenal insufficiency; concomitant strong CYP3A4 inhibitors
Monitoring	Serum K⁺ before starting, 4 weeks after, and periodically

Feature	Detail
Drugs	Semaglutide (Ozempic), liraglutide, dulaglutide ^[5]
Name breakdown	"GLP-1" = Glucagon-Like Peptide-1; "RA" = Receptor Agonist; "-glutide" suffix = GLP-1 RA
Mechanism	Mimics incretin GLP-1 → glucose-dependent insulin secretion (low hypo risk), ↓ glucagon, slows gastric emptying, ↑ satiety → weight loss. Direct renal effects: anti-inflammatory, anti-fibrotic, natriuretic
Renal evidence	FLOW trial (semaglutide) → ↓ kidney disease progression in T2DM with CKD
Advantages in DKD	No renal dose adjustment needed; promotes weight loss (important in obese T2DM); CV benefit (SUSTAIN-6, LEADER trials); can be used across all CKD stages
Side effects	GI (nausea, vomiting — dose-titrate slowly), pancreatitis (rare), injection site reactions
Contraindication	Personal/family history of medullary thyroid carcinoma or MEN2 (animal data showed C-cell tumours)

Parameter	Target	Drug
LDL-C	≤ 1.8 mmol/L (DM patients are "high risk" for CHD → intensive statin therapy) ^[4]^[7]	Statin (first line) ± ezetimibe

In patients with CKD 3–5 aged > 50, treatment with statin only or statin + ezetimibe is recommended regardless of baseline cholesterol ^[7]. Rationale: CKD 3–5 patients have ~10 per 1000 patient-year risk of coronary death/MI.

However, if the patient is already on dialysis, there is no recommendation to START a statin ^[7] — dialysis patients did not benefit from statin initiation in RCTs (AURORA, 4D trials), likely because the CV risk is driven more by calcification and arrhythmia than by classic atherosclerosis.

If nephrotic syndrome is present → hyperlipidaemia is common (↑ hepatic lipogenesis in response to ↓ oncotic pressure) → statins should be considered if hyperlipidaemia persists after treatment of underlying disorder and/or ACEI/ARB ^[20]^[21].

Intervention	Detail	Mechanism
Low sodium diet	~2 g Na/day	↓ ECF volume; enhances diuretic efficacy
Fluid restriction	If severe oedema/hyponatraemia	↓ Free water intake
Loop diuretics	Frusemide (furosemide) is usually preferred	Inhibits Na⁺/K⁺/2Cl⁻ co-transporter in thick ascending limb → natriuresis. High doses may be needed in nephrotic syndrome (gut wall oedema impairs oral absorption → consider IV if resistant) ^[20]
Add thiazide / K⁺-sparing diuretic	If loop alone insufficient	Sequential nephron blockade (thiazide blocks DCT; spironolactone blocks CD)
IV albumin	Reserved for diuretic-resistant oedema + hypoalbuminaemia	Transiently ↑ oncotic pressure → draws fluid from interstitium → enhances diuretic effect. Only as adjunct; rapidly excreted in urine
Monitor	Daily body weight (aim 1 kg/day loss), I/O, vitals, urine dipstick	Avoid over-diuresis → hypovolaemia → pre-renal AKI

As DKD progresses, the general complications of CKD emerge and must be managed:

Complication	Mechanism	Management
Anaemia	↓ EPO production by damaged peritubular fibroblasts	Erythropoiesis-stimulating agents (ESAs: epoetin, darbepoetin); IV iron if iron-deficient; target Hb 10–11.5 g/dL
CKD-MBD (mineral bone disease)	↓ 1,25-dihydroxyvitamin D → ↓ Ca²⁺ absorption → ↑ PTH (secondary hyperparathyroidism) → ↑ PO₄	Phosphate binders (calcium carbonate, sevelamer); active vitamin D (calcitriol/alfacalcidol); calcimimetics (cinacalcet) if tertiary HPT
Metabolic acidosis	↓ NH₄⁺ excretion; ↓ HCO₃⁻ regeneration	Oral NaHCO₃ supplementation (target HCO₃ ≥ 22 mmol/L)
Hyperkalaemia	Type 4 RTA + RAAS blockade + ↓ GFR	Low K⁺ diet; loop diuretics; potassium binders (sodium polystyrene sulphonate, patiromer, sodium zirconium cyclosilicate); adjust ACEI/ARB dose
Fluid overload	↓ Na⁺/water excretion	Salt restriction + diuretics; dialysis if refractory

RRT is indicated when eGFR < 15 mL/min (Stage 5 CKD / ESRD) or when there are uraemic symptoms or life-threatening complications unresponsive to medical therapy ^[2]^[13]^[23].

Modality	Detail	HK Context
Peritoneal dialysis (PD)	Uses peritoneal membrane as semipermeable membrane; patient self-administers at home (CAPD or APD)	HK has a PD-first policy if no contraindications ^[23]
Haemodialysis (HD)	Blood pumped through external dialyser via vascular access (AV fistula preferred); typically 3×/week, 4h/session	Used if contraindication to PD (e.g., peritoneal membrane failure, major abdominal surgery, repeated peritonitis) ^[23]
Renal transplantation	Living or deceased donor; best long-term survival and QoL	Considered for suitable candidates; requires lifelong immunosuppression

Contraindications ^[23]:

Modality	Contraindications
PD	Peritoneal membrane failure (from major abdominal surgery causing extensive scarring; long-term dextrose-containing PD fluids; repeated peritonitis)
HD	Poor cardiac function (cannot tolerate haemodynamic shifts); lack of suitable vascular access

Indications for emergency dialysis (mnemonic: AEIOU) ^[24]:

Letter	Indication	Detail
A	Acidosis	pH < 7.1 refractory to bicarbonate infusion
E	Electrolytes	K⁺ > 6.5 or rapidly rising, refractory to medical Rx
I	Intoxication	Drug removal in overdose (e.g., lithium, salicylates, methanol)
O	Overload	Fluid overload refractory to diuretics
U	Uraemia	Uraemic features: pericarditis, neuropathy, encephalopathy

Stage	Key Interventions
Prevention (healthy DM patients)	Good glycaemic control ^[1]
Incipient DKD (microalbuminuria — still reversible)	Good glycaemic control + treat risk factors (BP, smoking) + ACEI/ARB + SGLT2i + GLP-1 RA ^[1]^[5]
Overt DKD (macroalbuminuria, ↓GFR)	All of the above + finerenone + dietary modification + manage CKD complications + lipid management ^[1]^[5]
ESRD	RRT (PD/HD/transplant). Stop metformin and SGLT2i. Use linagliptin, glipizide, or insulin for glycaemic control ^[4]

Drug	Indication	Key Mechanism	Key Contraindication	Monitoring
ACEI/ARB	All DKD patients	↓ Efferent arteriolar tone → ↓ intraglomerular pressure → ↓ proteinuria	Bilateral RAS, K⁺ > 5.5, pregnancy, never combine ACEI + ARB	Cr + K⁺ at 1–2 weeks
SGLT2i	DKD with eGFR ≥ 20	Restores TGF → ↓ afferent arteriolar tone → ↓ hyperfiltration	ESRD/dialysis, T1DM (risk of euglycaemic DKA)	BG, K⁺, volume status, genital infection
Finerenone	Persistent albuminuria on max ACEI/ARB + SGLT2i	Blocks MR → ↓ fibrosis	K⁺ > 5.0, adrenal insufficiency, strong CYP3A4 inhibitors	K⁺ at baseline + 4 weeks
GLP-1 RA	T2DM with CKD, especially if obese	Incretin mimetic; anti-inflammatory + anti-fibrotic renal effects	MTC/MEN2 history	GI tolerance, BG
Statin ± ezetimibe	CKD 3–5 (not to START on dialysis)	↓ LDL-C, ↓ CV events	Active liver disease, myopathy	LFT, CK if symptomatic
Frusemide	Oedema	Loop diuretic → natriuresis	Anuria, severe hypovolaemia	Daily weight, I/O, K⁺
Insulin	All CKD stages	Exogenous insulin	Hypoglycaemia	BG (↓ dose in CKD as clearance reduced)
Linagliptin	DM with renal impairment	DPP-4 inhibitor, hepatobiliary elimination	Hypersensitivity	BG
Metformin	eGFR > 30 only	↓ Hepatic gluconeogenesis	eGFR < 30 (lactic acidosis risk)	eGFR, lactate if unwell

Parameter	Target	Source
HbA1c	≤ 7% (general); < 8% if comorbid/elderly)	^[2]^[13]^[22]
BP	< 130/80 mmHg (T2DM); < 120/75 (T1DM)	^[13]
LDL-C	≤ 1.8 mmol/L	^[4]
Proteinuria	< 1 g/day or uPCR < 0.5–1 g/g	^[20]^[21]
Follow-up	At least every 3 months	^[13]

High Yield Summary — Management of Diabetic Nephropathy

Foundational for ALL patients:

Lifestyle: smoking cessation, weight loss, exercise, low-salt diet
Glycaemic control: HbA1c ≤ 7% (prefer SGLT2i and GLP-1 RA)
BP control: < 130/80, ACEI or ARB first-line (BOTH antihypertensive AND renoprotective)
Statin ± ezetimibe for lipid management

Add-on for persistent albuminuria / progressive CKD: 5. SGLT2 inhibitor (massive reduction in renal failure risk) 6. Finerenone (non-steroidal MRA — reduces fibrosis, lower hyperkalaemia risk than spironolactone) 7. GLP-1 RA (semaglutide — weight loss, CV + renal benefit)

Advanced CKD/Nephrotic: 8. Loop diuretics ± thiazide for oedema 9. Manage complications: anaemia (ESAs), CKD-MBD, acidosis, hyperkalaemia 10. Dietary protein restriction 0.6–0.8 g/kg/day (but NOT in active nephrotic syndrome)

ESRD: 11. RRT: PD-first policy in HK → HD if contraindicated → transplant if suitable 12. Stop metformin + SGLT2i. Use linagliptin, glipizide, or insulin.

Key safety points:

Never combine ACEI + ARB
ACEI/ARB contraindicated in bilateral RAS
Check K⁺ after starting/changing ACEI/ARB or finerenone
Reduce insulin dose in CKD (reduced clearance → hypoglycaemia risk)

Active Recall — Management of Diabetic Nephropathy

References

^[1] Lecture slides: Block A - Deterioration of eyesight in a diabetic patient_ diabetic complications.pdf (Treatment of chronic complications, Management of hyperglycaemia) ^[2] Senior notes: Ryan Ho Endocrine.pdf (Section B. Diabetic Nephropathy Management, p.97) ^[3] Senior notes: Ryan Ho Urogenital.pdf (Section 3.4.6, p.84–85) ^[4] Senior notes: Maksim Medicine Notes.pdf (Diabetic nephropathy management, p.89; Macrovascular complications, p.88) ^[5] Senior notes: Block A - Nephrology Interactive Tutorial.pdf (Case P2 management, p.4) ^[7] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (Therapy aims, hyperlipidaemia, p.16–20) ^[9] Senior notes: Block A - Drugs and the Kidney.pdf (Linagliptin, p.2) ^[10] Lecture slides: GC_Interactive tutorial (Nephr case 2) student copy.pdf (Learning Objectives, p.1) ^[11] Senior notes: Block A – Nephrology Data Interpretation.pdf (Case 3, p.8–10; Drug-induced TIN, p.11) ^[13] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Management of DM nephropathy, p.1509–1511) ^[17] Senior notes: Endocrine Interactive Tutorial.pdf (ARB mechanism, management, p.6–7) ^[20] Senior notes: Ryan Ho Urogenital.pdf (General approach to GN management, p.76) ^[21] Senior notes: Ryan Ho Fundamentals.pdf (General approach to GN management, p.368) ^[22] Senior notes: Block A - Polyuria and polydipsia_ glucose metabolism; diabetes mellitus; diabetic ketoacidosis.pdf (HbA1c goals, p.18) ^[23] Senior notes: Block A - Renal Replacement Therapies.pdf (PD vs HD, contraindications, p.3) ^[24] Senior notes: Ryan Ho Critical Care.pdf (Dialysis indications AEIOU, p.26) ^[25] Senior notes: Block A - High blood pressure_ hypertension.pdf (Compelling indications, p.42)

Complications of Diabetic Nephropathy

Diabetic nephropathy generates complications through two converging streams: (1) complications arising from the nephrotic syndrome itself (when DKD progresses to nephrotic-range proteinuria), and (2) complications of progressive CKD (as GFR declines). On top of these, DKD patients carry the combined burden of diabetes-related and CKD-related cardiovascular risk, making them among the highest-risk patients you will encounter.

The complications are best understood in three categories:

Category	Source of Problem	Key Complications
A. Complications of nephrotic syndrome	Heavy proteinuria → hypoalbuminaemia → secondary systemic effects	Oedema, thromboembolism, infection, hyperlipidaemia/accelerated atherosclerosis, AKI
B. Complications of progressive CKD	↓ GFR → loss of renal excretory, endocrine, and metabolic functions	Fluid overload, hyperkalaemia, metabolic acidosis, anaemia, CKD-MBD, uraemia
C. Complications specific to the DM + CKD combination	Synergistic vascular damage; drug-related issues; co-existing microvascular and macrovascular disease	Cardiovascular death, Type 4 RTA, drug toxicity, diabetic foot, accelerated retinopathy/neuropathy

A. Complications of Nephrotic Syndrome

When DKD progresses to clinical nephrotic syndrome (proteinuria > 3.5 g/day, hypoalbuminaemia < 30 g/L, generalised oedema, hyperlipidaemia) ^[26], several important complications emerge. These are driven by the massive protein loss through the damaged glomerular filtration barrier.

Feature	Detail
Mechanism	Two theories work in parallel. Underfill theory: low oncotic pressure from hypoalbuminaemia → ↓ plasma volume → RAAS activation → Na⁺/water retention. Overfill theory: primary tubular sodium retention → volume expansion ^[26]. In practice, both contribute
Clinical features	Periorbital oedema (morning), bilateral ankle oedema (gravitational), ascites, pleural effusions, anasarca in severe cases
Why it can become resistant	Poor drug/diet compliance; frusemide malabsorption due to gut wall oedema (bowel wall is oedematous → oral loop diuretic is not absorbed properly) ^[14]
Management	Change to IV frusemide; add thiazide or potassium-sparing diuretics; IV albumin as adjunct to diuretics (transiently ↑ oncotic pressure to mobilise interstitial fluid, then diurese) ^[14]

This is one of the most feared complications of nephrotic syndrome.

Feature	Detail
Mechanism	Hypercoagulability from compensatory production of clotting factors by the liver (the liver ramps up protein synthesis non-specifically in response to ↓ oncotic pressure — this includes procoagulant factors like fibrinogen, factors V, VII, VIII) + urinary loss of antithrombin III (a natural anticoagulant, ~65 kDa, small enough to be lost through the damaged GBM) ^[14]^[26]
Common thrombotic events	Deep vein thrombosis (DVT), renal vein thrombosis (particularly associated with membranous nephropathy, but can occur in DKD too), pulmonary embolism
Renal vein thrombosis	Presents with sudden loin pain, gross haematuria, acute ↑ proteinuria, and AKI. Diagnose with Doppler USG or CT angiography ^[14]
Management	If AKI: thrombolysis ± embolectomy. If non-AKI: LMWH/UFH → warfarin for minimum 6–12 months while still nephrotic ^[14]. DVT prophylaxis: compressive stockings ± anticoagulation if high risk ^[14]

Exam Pearl: Why Nephrotic Patients Clot

The hypercoagulable state in nephrotic syndrome is driven by a mismatch: the liver increases production of ALL proteins (including procoagulants) to compensate for hypoalbuminaemia, while the kidneys selectively lose small anticoagulant proteins (antithrombin III, protein C, protein S) in the urine. The net effect is a shifted balance towards thrombosis.

Feature	Detail
Mechanism	Loss of immunoglobulins (Ig) in the urine — particularly IgG (~150 kDa, can be lost when the GBM is severely damaged) + loss of complement factors → impaired opsonisation and humoral immunity ^[14]^[26]
Common infections	Spontaneous bacterial peritonitis (SBP — only in children with ascites from nephrotic syndrome ^[14]), cellulitis, pneumonia (especially pneumococcal), UTI
Management	Prompt antibiotics; pneumococcal vaccination is indicated for ALL nephrotic patients ^[21]

Feature	Detail
Mechanism	↑ Hepatic lipogenesis (↑ HMG-CoA reductase activity) — a non-specific reaction to falling oncotic pressure ^[26]. Also ↓ lipoprotein lipase activity (less clearance of TG-rich particles) + urinary loss of HDL
Pattern	↑ LDL, ↑ VLDL, ↑ TG, ↓ HDL
Consequence	Accelerated atherosclerosis → ↑ risk of MI, stroke, PVD — on top of the already elevated CV risk from DM
Management	Statins (drug of choice) — consider if hyperlipidaemia persists after treatment of underlying disorder and/or ACEI/ARB ^[20]^[21]. In CKD 3–5: statin ± ezetimibe ^[7]

Feature	Detail
Mechanism	Hypovolaemia due to over-diuresis (underfilling when you diurese too aggressively in a nephrotic patient → pre-renal AKI); ATN (from prolonged hypoperfusion); crescentic transformation (RPGN) (rare but devastating — immune-mediated crescent formation superimposed on existing DKD) ^[14]
Management	Lower dose or withhold diuretics; rehydration. If RPGN → urgent biopsy and immunosuppression ^[14]

B. Complications of Progressive CKD

As DKD progresses through CKD stages 3–5, the complications of CKD itself accumulate. The 6 systemic complications of CKD from the GC lecture ^[7]:

Fluid retention, metabolic acidosis, high blood pressure, normochromic normocytic anaemia, secondary hyperparathyroidism, bone disease ^[7]

Feature	Detail
Mechanism	↓ Nephron mass → ↓ Na⁺/water excretion → ECF volume expansion → oedema + hypertension. This is a vicious cycle: hypertension further damages remaining nephrons
Clinical	Peripheral oedema, raised JVP, pulmonary oedema, hypertension
Management	Salt restriction, loop diuretics, BP control (ACEI/ARB first-line). Dialysis if refractory ^[14]

Feature	Detail
Mechanism	Three converging factors: (1) ↓ GFR → ↓ K⁺ excretion; (2) Type 4 RTA — destruction of JGA by vascular hyalinosis → hyporeninemic hypoaldosteronism → ↓ aldosterone → ↓ K⁺ secretion at collecting duct ^[5]; (3) RAAS blockade (ACEI/ARB) and finerenone further ↓ aldosterone
Clinical	Often asymptomatic until severe (K⁺ > 6.0 mmol/L). ECG changes: peaked T waves → widened QRS → sine wave → VF/asystole. Muscle weakness, paraesthesia
Management	Low K⁺ diet ( < 1 mmol/kg/day); loop diuretics; potassium binders (sodium polystyrene sulphonate / Resonium, patiromer, sodium zirconium cyclosilicate); review drugs (ACEI/ARB dose, stop NSAIDs); NaHCO₃ if acidotic. Emergency: IV calcium gluconate (stabilise myocardium), insulin-dextrose infusion, nebulised salbutamol, dialysis ^[14]

Type 4 RTA in DKD — Why It Matters

Hyporeninemic hypoaldosteronism (Type 4 RTA): the most common cause in adults is diabetic nephropathy — destruction of JG apparatus due to vascular hyalinosis ^[5]. This produces a characteristic picture of hyperkalaemia + mild hyperchloraemic metabolic acidosis (non-anion-gap). Management: stop or reduce inciting drugs; loop diuretics + low K⁺ diet ^[27].

Feature	Detail
Mechanism	↓ Ammoniagenesis (fewer functioning proximal tubular cells to generate NH₃ for H⁺ buffering) → ↓ net acid excretion. Also ↓ HCO₃⁻ regeneration by the kidney. In early CKD: non-anion-gap (Type 4 RTA). In late CKD (Stage 4–5): high anion gap (retained uraemic anions: sulphate, phosphate, hippurate)
Clinical	Kussmaul breathing (deep, rapid — respiratory compensation), fatigue, anorexia. Chronic acidosis accelerates muscle wasting and bone resorption
Management	Oral NaHCO₃ supplementation (target serum HCO₃ ≥ 22 mmol/L). Dialysis if refractory ^[14]^[27]

Feature	Detail
Mechanism	Normochromic normocytic anaemia — primarily from ↓ erythropoietin (EPO) production by damaged peritubular interstitial fibroblasts. Also: iron deficiency (↑ hepcidin in CKD → ↓ iron absorption and ↓ iron release from stores), chronic inflammation (cytokine-mediated), uraemic toxins (suppress erythropoiesis), reduced RBC survival
Clinical	Fatigue, pallor, exertional dyspnoea, angina in severe cases
Investigation	CBC (NcNc anaemia); iron studies: TSAT and ferritin (ferritin alone NOT useful — affected by CKD and inflammation) ^[14]. TSAT < 20% + ferritin < 100 (non-dialysis/PD) or < 200 (HD) = iron-deficiency component
Management	IV iron (Monofer) — avoid oral due to ↑ hepcidin (impairs oral iron absorption) ^[14]. If still anaemic: EPO-stimulating agents (ESAs): darbepoetin SC Q4 weekly, mircera SC ^[14]. Target Hb 10–11.5 g/dL (avoid > 13 g/dL — ↑ CV events)

Feature	Detail
Mechanism	↓ Functional renal mass → ↓ 1α-hydroxylase activity → ↓ 1,25-dihydroxyvitamin D (calcitriol) production → ↓ intestinal Ca²⁺ absorption → hypocalcaemia. Simultaneously, ↓ GFR → ↓ phosphate excretion → hyperphosphataemia. Both stimulate PTH release → secondary hyperparathyroidism, which causes bone resorption (renal osteodystrophy), vascular calcification, and pruritus
Biochemistry	↓ Ca²⁺, ↑ PO₄²⁻, ↑ PTH, ↓ active Vitamin D
Clinical	Bone pain, fractures (osteodystrophy), metastatic calcification (vessels, soft tissues), uraemic pruritus (partly from Ca-PO₄ deposition in skin)
Vascular calcification	CKD-MBD is characterised by vascular calcification ^[7] — calcium-phosphate product deposition in vessel walls → arterial stiffness → systolic HTN → LVH → heart failure, and coronary artery calcification → MI
Management	Phosphate binders (calcium carbonate, sevelamer, lanthanum) — taken with meals to bind dietary phosphate; active Vitamin D (calcitriol or alfacalcidol); calcimimetics (cinacalcet — ↓ PTH secretion by activating CaSR on parathyroid gland) if refractory; low-phosphate diet ( < 800 mg/day) ^[14]

Feature	Detail
Mechanism	Accumulation of uraemic toxins (urea, creatinine, middle molecules, protein-bound solutes) in Stage 5 CKD
Systems affected	CNS (encephalopathy, asterixis), PNS (uraemic neuropathy), GI (nausea, vomiting, anorexia, GI bleeding), CV (uraemic pericarditis — a medical emergency and indication for urgent dialysis), Skin (pruritus, café-au-lait colour from urochrome deposition), Haematological (platelet dysfunction → bleeding tendency)
Management	Renal replacement therapy (dialysis or transplant) — the definitive treatment for uraemia. Indications for emergency dialysis: AEIOU (Acidosis, Electrolytes, Intoxication, Overload, Uraemia) ^[24]

C. Complications Specific to the DM + CKD Combination

DKD patients face unique complications that arise from the synergistic interaction of diabetes and kidney failure.

Feature	Detail
Why so high?	DM doubles CV risk. CKD independently doubles CV risk. Together, the risk is more than additive — DKD patients have ~10× the CV mortality of age-matched healthy controls
IHD	Accounts for 70% of deaths in DM ^[2]^[4]. Risk of MI is 3–5× higher ^[4]. DKD amplifies this through HTN, dyslipidaemia, endothelial dysfunction, vascular calcification, and proteinuria (which is an independent CV risk factor)
Ischaemic stroke	Risk 2.5× higher ^[4]
Peripheral arterial disease	Intermittent claudication, foot ulcer, foot gangrene. Risk of lower limb amputation 15× higher ^[4]. Compounded by diabetic neuropathy (loss of protective sensation → unnoticed trauma)
Management	BP < 130/80; LDL ≤ 1.8; smoking cessation ^[4]. Antiplatelet therapy (aspirin if indicated). SGLT2i and GLP-1 RA have proven CV mortality benefit on top of renoprotection

GC 042 Lecture Slide — Chronic Diabetic Complications

Microvascular (small vessel disease):

Retinopathy
Nephropathy (glomerulosclerosis): microalbuminuria → albuminuria (proteinuria) → raised serum creatinine → end-stage renal failure
Neuropathy: peripheral; autonomic; acute mononeuropathy; diabetic amyotrophy

Macrovascular (large vessel disease):

Stroke; coronary and peripheral artery diseases

^[1]^[28]

DKD patients are especially vulnerable to drug-related complications because:

Altered clearance +/- increased susceptibility to adverse effects due to reduced renal function ^[29]
CKD increases susceptibility to both direct and indirect injury — someone with background CKD is even more susceptible to further renal injury ^[29]

Key examples:

Drug	Complication in CKD	Why
Metformin	Lactic acidosis	Renally cleared; accumulates when eGFR < 30
NSAIDs	AKI, tubulointerstitial nephritis, GN	Inhibit protective prostaglandins → ↓ renal blood flow ^[11]
ACEI/ARB	Hyperkalaemia, AKI (especially if bilateral RAS)	↓ Aldosterone + ↓ efferent arteriolar tone ^[11]
Insulin / sulphonylureas	Hypoglycaemia	Insulin clearance is reduced in CKD → prolonged action; SU active metabolites accumulate
Contrast agents	Contrast nephropathy (AKI)	GFR < 30: contraindicated for contrast ^[14]

"Drugs can damage the kidneys in many ways" ^[29]. Three principles: avoid further nephrotoxic insult; attention to correct dose; beware of side effects in patients with impaired kidney function ^[29].

DKD almost never occurs in isolation ^[2]. The same pathophysiology (hyperglycaemia → AGEs, ROS, PKC activation) damages all microvasculature simultaneously:

Complication	Prevalence with DKD	Clinical Implication
Diabetic retinopathy	90% in T1DM; ~70% in T2DM ^[2]	May progress to blindness (vitreous haemorrhage, retinal detachment, DMO). Requires annual dilated eye exam + ophthalmology referral
Diabetic neuropathy	70–90% ^[2]	Peripheral sensory neuropathy → loss of protective sensation → foot ulcers → gangrene → amputation. Autonomic neuropathy → postural hypotension (dangerous with diuretics), gastroparesis (affects drug absorption), neurogenic bladder (↑ UTI risk → further renal damage)
Diabetic foot	Very common in DKD	The convergence of neuropathy + PVD + immunosuppression (from both DM and CKD) creates the "diabetic foot" — a devastating complication. Risk of lower limb amputation 15× higher ^[4]

Feature	Detail
Timeline	ESRD develops between 5–15 years after onset of gross proteinuria ^[13]
Rate of GFR decline	~10 mL/min/year untreated; slowed to ~2–3 mL/min/year with optimal RAAS blockade + SGLT2i
RRT requirements	HK PD-first policy ^[23]. Diabetic ESRD patients on dialysis have worse outcomes than non-diabetic ESRD patients (higher CV mortality, infection risk, worse glycaemic control)
Renal transplantation	Best survival and QoL for suitable candidates. Combined pancreas-kidney transplant may be considered for T1DM patients

Factor	Mechanism
Hyperglycaemia	Impairs neutrophil chemotaxis, phagocytosis, and oxidative killing
Uraemia	Impairs T-cell and B-cell function
Urinary Ig loss (nephrotic)	↓ Humoral immunity
Dialysis access	Portal of entry for bacteria (Tenckhoff catheter → peritonitis in PD; AV fistula → bacteraemia in HD)
Common infections	UTI, pneumonia, TB reactivation (DM is a very common cause of TB reactivation) ^[17], peritonitis (PD patients), bacteraemia (HD patients)
Management	Vaccination: influenza, pneumococcus, HBV ^[14]; prompt antibiotics; low threshold for investigation

Complication	Category	Mechanism	Key Management
Oedema / anasarca	Nephrotic	↓ Oncotic pressure + Na retention	Diuretics (IV if resistant), salt restriction, IV albumin
Thromboembolism (DVT, RVT, PE)	Nephrotic	↑ Procoagulants, ↓ AT-III	Anticoagulation; compressive stockings
Infection	Nephrotic + CKD + DM	Ig loss, complement loss, uraemia, hyperglycaemia	Antibiotics, vaccination
Hyperlipidaemia	Nephrotic	↑ Hepatic lipogenesis from ↓ oncotic pressure	Statins
Hyperkalaemia	CKD + Type 4 RTA + RAAS drugs	↓ Excretion, ↓ aldosterone	Low K diet, diuretics, K binders, adjust RAAS drugs
Metabolic acidosis	CKD + Type 4 RTA	↓ NH₃ genesis, ↓ HCO₃ regen, retained uraemic anions	Oral NaHCO₃, dialysis
Anaemia	CKD	↓ EPO, ↑ hepcidin, chronic inflammation	IV iron, ESAs
CKD-MBD	CKD	↓ Calcitriol → ↓Ca, ↑PO₄ → secondary HPT	PO₄ binders, Vitamin D, calcimimetics
Cardiovascular disease	DM + CKD (synergistic)	Atherosclerosis, vascular calcification, HTN	BP control, statins, SGLT2i, GLP-1 RA
Drug toxicity	CKD	Altered clearance, ↑ susceptibility	Dose adjustment, avoid nephrotoxins
ESRD	Progression of DKD	End-stage nephron loss	RRT: PD, HD, transplant
Diabetic foot	DM neuropathy + PVD + CKD immunosuppression	Loss of sensation + ischaemia + infection	Foot care, screening, vascular surgery
Uraemia	Advanced CKD	Toxin accumulation	Dialysis

High Yield Summary — Complications of Diabetic Nephropathy

Complications of Nephrotic Syndrome:

Oedema (resistant → IV frusemide, IV albumin)
Thromboembolism (loss of antithrombin III, ↑ hepatic procoagulant synthesis → DVT, renal vein thrombosis, PE)
Infection (Ig loss, complement loss → SBP in children, pneumonia → vaccinate)
Hyperlipidaemia (↑ hepatic lipogenesis → accelerated atherosclerosis)
AKI (over-diuresis, ATN, RPGN transformation)

Complications of CKD (the 6 from the lecture):

Fluid retention, metabolic acidosis, hypertension, normochromic normocytic anaemia, secondary hyperparathyroidism, bone disease

DM + CKD Synergistic Complications:

CV disease is the #1 killer (IHD accounts for 70% deaths in DM; CKD amplifies risk)
Type 4 RTA (hyporeninemic hypoaldosteronism → hyperkalaemia)
Drug toxicity (altered clearance — adjust doses, avoid nephrotoxins)
Co-existing retinopathy, neuropathy, diabetic foot
↑ Infection risk (TB reactivation, UTI, peritonitis)
Progression to ESRD (5–15y after gross proteinuria onset)

Active Recall — Complications of Diabetic Nephropathy

References

^[1] Lecture slides: Block A - Deterioration of eyesight in a diabetic patient_ diabetic complications.pdf (Chronic Diabetic Complications section) ^[2] Senior notes: Ryan Ho Endocrine.pdf (Section 4.1.4.2 Chronic Diabetic Complications, p.94) ^[4] Senior notes: Maksim Medicine Notes.pdf (Complications of DM, macrovascular/microvascular, p.88) ^[5] Senior notes: Block A - Nephrology Interactive Tutorial.pdf (Case P2 — Type 4 RTA, p.4) ^[7] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (6 systemic complications, p.23) ^[11] Senior notes: Block A – Nephrology Data Interpretation.pdf (Drug-induced TIN, NSAID/ACEI, p.11) ^[13] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Management of DM nephropathy, ESRD timeline, p.1509) ^[14] Senior notes: Maksim Medicine Notes.pdf (CKD complications management, p.218–220; Nephrotic complications, p.232) ^[17] Senior notes: Endocrine Interactive Tutorial.pdf (TB reactivation, p.6) ^[20] Senior notes: Ryan Ho Urogenital.pdf (General approach to GN management, p.76) ^[21] Senior notes: Ryan Ho Fundamentals.pdf (Pneumococcal vaccination, diuretics, statins, p.368) ^[23] Senior notes: Block A - Renal Replacement Therapies.pdf (PD-first policy, contraindications, p.3) ^[24] Senior notes: Ryan Ho Critical Care.pdf (AEIOU dialysis indications, p.26) ^[26] Senior notes: learning_points_output.txt (Nephrotic syndrome complications learning points) ^[27] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf (Type 4 RTA management, p.16) ^[28] Lecture slides: GC 042. Deterioration of eyesight in a diabetic patient diabetic complications [Update 2025].pdf (Chronic Diabetic Complications, p.7–8, 15) ^[29] Senior notes: Block A - Drugs and the Kidney.pdf (Drug use in impaired renal function, p.1)

High Yield Summary

Definition: Persistent albuminuria (UACR > 30 mg/g) or proteinuria (> 500 mg/day) in a DM patient without other renal disease.

Epidemiology: Leading cause of ESRD worldwide (~50%); in HK, accounts for ~35–51% of ESRD cases.

Risk Factors: Duration of DM, poor glycaemic control (↑HbA1c), hypertension, glomerular hyperfiltration, obesity, smoking, genetic susceptibility.

Pathophysiology (Two Arms):

Metabolic: AGEs, polyol pathway, PKC activation, hexosamine pathway, ROS (unifying mechanism) → ECM accumulation, GBM thickening, podocyte injury
Haemodynamic: Afferent arteriolar dilatation (↑SGLT2 → ↑Na reabsorption → ↓NaCl at macula densa → TGF reset) → intraglomerular hypertension → glomerular injury. RAAS activation constricts efferent arteriole → further ↑intraglomerular pressure.

Histology: GBM thickening, mesangial expansion, Kimmelstiel-Wilson nodules (pathognomonic), afferent + efferent arteriolar hyalinosis.

Stages: Hyperfiltration → Normoalbuminuria → Microalbuminuria (30–300 mg/day) → Macroalbuminuria (> 300 mg/day) → ESRD.

Red Flags for Non-DKD: Haematuria (especially active sediment), rapid GFR decline, short DM duration, absence of retinopathy, systemic features.

Screening: UACR — at diagnosis for T2DM; 5 years post-diagnosis for T1DM. Annual thereafter.

Key Drugs (preview): ACEI/ARB (RAAS blockade), SGLT2i (restore TGF, ↓intraglomerular pressure), finerenone (non-steroidal MRA, ↓fibrosis), GLP-1 RA. Glycaemic target HbA1c < 7–8%.

High Yield Summary — DDx of Diabetic Nephropathy

When a DM patient presents with proteinuria and/or ↓GFR:

Most likely diagnosis: Diabetic nephropathy (~51% of renal impairment in DM).
Red flags for non-DKD (HARSH): Haematuria/active sediment, Absence of retinopathy, Rapid GFR decline, Short DM duration, High suspicion for systemic disease.
Key DDx with nephrotic features (bland sediment): Membranous nephropathy (especially HBV-related in HK), FSGS, amyloidosis, MCD (NSAID-induced), light chain deposition disease/myeloma.
Key DDx with nephritic features (active sediment): IgA nephropathy, lupus nephritis, RPGN, MPGN — these are almost certainly NOT DKD.
Non-glomerular DDx: Drug-induced AKI (NSAIDs, ACEI/ARB), renal artery stenosis, obstructive uropathy, TIN.
Renal biopsy is indicated only if atypical features are present.
DKD sits under secondary non-proliferative (nephrotic) glomerulopathies in the classification table.
Always check fundoscopy: presence of diabetic retinopathy strongly supports DKD; its absence is a major red flag.

High Yield Summary — Diagnostic Approach

Diabetic nephropathy is a clinical diagnosis made when ALL of the following are present:

Established DM of adequate duration
Persistent albuminuria (confirmed on ≥ 2 of 3 samples)
Bland urinary sediment (no RBC, no casts)
Other microvascular complications present (especially diabetic retinopathy)
No features of alternative renal disease

Key investigations:

UACR (screening and quantification — first morning void)
Serum creatinine + eGFR (staging)
Urine microscopy (bland vs active sediment — the key differentiator)
Dilated fundoscopy (presence/absence of retinopathy — the key clinical supportive evidence)
USS kidneys (size, exclude obstruction)
Renal biopsy — ONLY if atypical features (active sediment, no retinopathy, rapid GFR decline, short DM duration, systemic features, significant ↓GFR after ACEI/ARB)

Histology (when biopsy done):

GBM thickening, mesangial expansion, Kimmelstiel-Wilson nodules, afferent + efferent arteriolar hyalinosis
RPS Classification: Class I (GBM thickening) → Class IV (advanced sclerosis > 50% glomeruli)

High Yield Summary — Management of Diabetic Nephropathy

Foundational for ALL patients:

Lifestyle: smoking cessation, weight loss, exercise, low-salt diet
Glycaemic control: HbA1c ≤ 7% (prefer SGLT2i and GLP-1 RA)
BP control: < 130/80, ACEI or ARB first-line (BOTH antihypertensive AND renoprotective)
Statin ± ezetimibe for lipid management

ESRD: 11. RRT: PD-first policy in HK → HD if contraindicated → transplant if suitable 12. Stop metformin + SGLT2i. Use linagliptin, glipizide, or insulin.

Key safety points:

Never combine ACEI + ARB
ACEI/ARB contraindicated in bilateral RAS
Check K⁺ after starting/changing ACEI/ARB or finerenone
Reduce insulin dose in CKD (reduced clearance → hypoglycaemia risk)

High Yield Summary — Complications of Diabetic Nephropathy

Complications of Nephrotic Syndrome:

Oedema (resistant → IV frusemide, IV albumin)
Thromboembolism (loss of antithrombin III, ↑ hepatic procoagulant synthesis → DVT, renal vein thrombosis, PE)
Infection (Ig loss, complement loss → SBP in children, pneumonia → vaccinate)
Hyperlipidaemia (↑ hepatic lipogenesis → accelerated atherosclerosis)
AKI (over-diuresis, ATN, RPGN transformation)

Complications of CKD (the 6 from the lecture):

Fluid retention, metabolic acidosis, hypertension, normochromic normocytic anaemia, secondary hyperparathyroidism, bone disease

DM + CKD Synergistic Complications:

CV disease is the #1 killer (IHD accounts for 70% deaths in DM; CKD amplifies risk)
Type 4 RTA (hyporeninemic hypoaldosteronism → hyperkalaemia)
Drug toxicity (altered clearance — adjust doses, avoid nephrotoxins)
Co-existing retinopathy, neuropathy, diabetic foot
↑ Infection risk (TB reactivation, UTI, peritonitis)
Progression to ESRD (5–15y after gross proteinuria onset)

Diabetic Nephropathy

Definition

Epidemiology

Risk Factors

Non-Modifiable Risk Factors

Modifiable Risk Factors

Anatomy and Function: The Glomerular Filtration Barrier

Normal Glomerular Structure

Mesangium

Juxtaglomerular Apparatus (JGA)

Etiology (Focus on Hong Kong Context)

Why Is DKD So Common in Hong Kong?

Causes of CKD in Hong Kong (for context)

Pathophysiology

Overview: The Two Arms of Injury

1. Metabolic Pathways of Injury

a) Advanced Glycation End-products (AGEs)

b) Polyol (Sorbitol) Pathway

c) Protein Kinase C (PKC) Activation

d) Hexosamine Pathway

e) Reactive Oxygen Species (ROS)

2. Haemodynamic Injury

a) Glomerular Hyperfiltration

b) Systemic Hypertension

c) RAAS Activation

3. Cytokine and Growth Factor Pathways

4. Tubulointerstitial Fibrosis (the Final Common Pathway)

Histopathology

Classification: Natural History / Stages of Diabetic Nephropathy

Clinical Features

Symptoms

Signs

Screening for Diabetic Nephropathy

Red Flags: When It Is NOT Diabetic Nephropathy

Key Associations Worth Noting

Nephrotic Syndrome in DKD

DKD and Cardiovascular Risk

Type 4 RTA

Association with Other Diabetic Complications

Interactive Tutorial Case Points (High Yield for Exam)

Pathogenesis of Chronic Diabetic Complications — Unifying Framework

Treatment Principles (Preview — Detailed Management Will Follow)

Active Recall - Diabetic Nephropathy (Definition, Epidemiology, Pathophysiology, Clinical Features)

References

The Clinical Problem

Framework: How to Think About the DDx

Diagnostic Decision Tree

Comprehensive Differential Diagnosis Table

A. Conditions That Mimic DKD (Non-Diabetic Renal Disease in a Diabetic Patient)

B. Conditions That Present with Active Sediment (Nephritic Features) — Clearly Not DKD

C. Non-Glomerular Causes of Renal Impairment in DM Patients

D. Special Mention: Co-existing Diabetic Nephropathy + Another Renal Disease

Nephrotic vs Nephritic Presentation — Where Does DKD Sit?

The GC Interactive Tutorial Case (Worked Example)

Kidney Size on USS — A Rapid DDx Tool

Drug-Induced AKI Superimposed on DKD

Summary: Approach to DDx

Active Recall — Differential Diagnosis of Diabetic Nephropathy

Diagnostic Criteria

Clinical Diagnostic Criteria

Albuminuria Categories (KDIGO)

Renal Pathology Society (RPS) Classification of Diabetic Nephropathy (Histological — for biopsy cases)

Diagnostic Algorithm

Investigation Modalities: Detailed Breakdown

A. Urine Investigations

B. Blood Investigations

C. Immunological Workup (When Red Flags Present)

D. Imaging

E. Fundoscopy

F. Renal Biopsy

Interpretation Framework: Putting It All Together

Screening Protocol Summary

Diagnostic Approach from the GC Interactive Tutorial Case

Active Recall — Diagnostic Criteria, Algorithm, and Investigations for Diabetic Nephropathy

Management Philosophy

Management Algorithm (Overview Diagram)

Detailed Management by Pillar

Pillar 1: Lifestyle Modification

Pillar 2: Glycaemic Control

Pillar 3: Blood Pressure Control